Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

June 1, 2022

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL LGL-L PTCL Solid Tumors
Read More
June 1, 2022

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MYD88 Tumors
Read More
April 7, 2022

KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

American Association for Cancer Research Annual Meeting
Liquid Tumors Solid Tumors
Read More
December 13, 2021

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
December 13, 2021

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
November 12, 2021

Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition

SITC 2021
Liquid Tumors Solid Tumors
Read More
October 27, 2021

Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications

4th Annual TPD Summit
Liquid Tumors Solid Tumors
Read More
July 12, 2021

Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL

13th Annual T-Cell Lymphoma Forum
PTCL
Read More
June 20, 2021

KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
MYD88 Tumors
Read More
April 10, 2021

Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers

American Association of Cancer Research (AACR) 2021 Annual Meeting
MYD88 Tumors
Read More